Page last updated: 2024-11-05

lactobionic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Lactobionic acid is a sugar acid derived from lactose. It is synthesized by oxidizing the aldehyde group of lactose to a carboxyl group. It is commonly produced through enzymatic oxidation of lactose using a bacterial enzyme, lactobionic acid dehydrogenase. It is a non-toxic, biodegradable, and highly water-soluble compound. Lactobionic acid is being studied for its potential applications in various fields due to its unique properties. It has shown promise as a chelating agent for metal ions, particularly iron. This property makes it useful in the development of iron-chelating agents for treating iron overload disorders. It is also being investigated for its potential antioxidant properties. Lactobionic acid's ability to scavenge free radicals and protect cells from oxidative damage is a key area of research. Additionally, lactobionic acid has shown potential as a carrier for drug delivery systems, particularly in ophthalmic applications. Its ability to form complexes with drugs and enhance their solubility and stability makes it a promising candidate for targeted drug delivery. The research on lactobionic acid continues to explore its various applications, particularly in the pharmaceutical and biomedical industries.'

Cross-References

ID SourceID
PubMed CID7314
CHEMBL ID3039602
CHEBI ID55481
SCHEMBL ID24870
MeSH IDM0047257

Synonyms (66)

Synonym
PRESTWICK3_000452
PRESTWICK2_000452
110638-68-1
lactobionic acid ,
96-82-2
PRESTWICK_560
NCGC00016356-01
cas-96-82-2
BPBIO1_000578
BSPBIO_000524
NCGC00179532-01
lactobionic acid, cell impermeant agent
PRESTWICK1_000452
SPBIO_002463
PRESTWICK0_000452
D0229170-C0EC-40FC-A777-BF34018EED2A
4-o-beta-d-galactopyranosyl-d-gluconic acid
4-(beta-d-galactosido)-d-gluconic acid
CHEBI:55481 ,
(2r,3r,4r,5r)-2,3,5,6-tetrahydroxy-4-[(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexanoic acid
L0005
HMS1569K06
HMS2096K06
65r938s4dv ,
einecs 202-538-3
unii-65r938s4dv
dtxcid6028787
dtxsid3048861 ,
tox21_113353
AKOS015924795
lactobionic acid [ep monograph]
lactobionic acid [ii]
d-gluconic acid, 4-o-.beta.-d-galactopyranosyl-
lactobionic acid [ep impurity]
lactobionic acid [who-dd]
lactobionic acid [inci]
lactobionic acid [mi]
lactobionic acid [mart.]
lactobionic acid [usp-rs]
AKOS015896798
S4964
CCG-214227
2,3,5,6-tetrahydroxy-4-[(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]oxy-hexanoic acid
SCHEMBL24870
tox21_113353_1
NCGC00179532-03
(2r,3r,4r,5r)-2,3,5,6-tetrahydroxy-4-[(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]oxy-hexanoic acid
CHEMBL3039602
mfcd00078147
methyl (r)-(-)-2-chloromandelate
lactobionic acid, purum
lactobionic acid, 97%
4-o-beta-galactopyranosyl-d-gluconic acid
lactobionic acid, european pharmacopoeia (ep) reference standard
Q6138969
JYTUSYBCFIZPBE-AMTLMPIISA-N
(2r,3r,4r,5r)-2,3,5,6-tetrahydroxy-4-(((2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2h-pyran-2-yl)oxy)hexanoic acid
(2r,3r,4r,5r)-2,3,5,6-tetrahydroxy-4-((2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2h-pyran-2-yloxy)hexanoic acid
AS-16070
maltobionic-acid
AMY32686
d-gluconic acid, 4-o-b-d-galactopyranosyl-
D70310
CS-W011829
HY-N7059
4-o-ss-d-galactopyranosyl-d-gluconic acid

Research Excerpts

Overview

Lactobionic acid (LA) is a ligand for the asialoglycoprotein receptors which are overexpressed on the membrane of hepatocellular carcinoma cells. Lactobionics acid (LBA) is an organic acid with multiple biological activities that has recently been a focus of interest as an antibacterial agent.

ExcerptReferenceRelevance
"Lactobionic acid (LBA) is a specialty organic acid that is widely employed in the food, cosmetic, and pharmaceutical industries. "( Isolation of new lactobionic acid-producing microorganisms and improvement of their production ability by heterologous expression of glucose dehydrogenase from Pseudomonas taetrolens.
Eom, GT; Jeong, BY; Lee, SS; Oh, YR, 2022
)
2.5
"Lactobionic acid (LBA) is an organic acid with multiple biological activities that has recently been a focus of interest as an antibacterial agent."( Inhibitory effects of lactobionic acid on Vibrio parahaemolyticus planktonic cells and biofilms.
Fan, Q; Sheng, Q; Song, W; Yuan, Y; Yue, T; Zhang, T, 2022
)
1.76
"Lactobionic acid (LBA) is a bioactive molecule that has generated keen interest in different industries. "( The antimicrobial and bioactive properties of lactobionic acid.
Díaz, M; Marcet, I; Rendueles, M; Sáez-Orviz, S, 2022
)
2.42
"Lactobionic acid (LA) is a ligand for the asialoglycoprotein receptors which are overexpressed on the membrane of hepatocellular carcinoma cells."( Conjugates of lactobionic acid and IR820: New photosensitizers for efficient photodynamic therapy of hepatoma cells.
Du, K; Hu, H; Tao, Y; Xiao, W; Xu, D; Xu, Q; Yuan, X, 2022
)
1.8
"Lactobionic acid (LBA) is a natural polyhydroxy acid widely used in the food industry."( iTRAQ-based quantitative proteomic analysis of the antimicrobial mechanism of lactobionic acid against
Cao, J; Zheng, Y, 2021
)
1.57
"Lactobionic acid is a highly moisturizing agent. "( Comparative evaluation of skin moisture after topical application of 10% and 30% lactobionic acid.
Algiert-Zielińska, B; Mucha, P; Rotsztejn, H, 2018
)
2.15
"Lactobionic acid (LBA) is a fine chemical largely applied in the food, chemical, cosmetics and pharmaceutical industries. "( Potential use of ricotta cheese whey for the production of lactobionic acid by Pseudomonas taetrolens strains.
De Giorgi, S; Fabbri, A; Fava, F; Gallina Toschi, T; Raddadi, N, 2018
)
2.17
"Lactobionic acid (LBA) is a newly identified natural polyhydroxy acid that is widely used in the food industry. "( Antibacterial activity and mechanism of lactobionic acid against Staphylococcus aureus.
Cao, J; Fu, H; Gao, L; Zheng, Y, 2019
)
2.22
"Lactobionic acid (LBA) is a bionic acid naturally found in the "Caspian Sea yogurt" and chemically constituted of a gluconic acid bonded to a galactose. "( Lactobionic Acid as a Potential Food Ingredient: Recent Studies and Applications.
Cardoso, T; Dagostin, JLA; Marques, C; Masson, ML, 2019
)
3.4
"Lactobionic acid is a relatively new product derived from lactose oxidation, with high potential applications as a bioactive compound. "( The utilization of Pseudomonas taetrolens to produce lactobionic acid.
Czarnecki, Z; Goderska, K; Szwengiel, A, 2014
)
2.09
"Lactobionic acid (LA) is a newer cosmeceutical active belonging to the class of alpha-hydroxyacids (AHAs), showing advantages over them. "( Lactobionic acid in a natural alkylpolyglucoside-based vehicle: assessing safety and efficacy aspects in comparison to glycolic acid.
Lukic, M; Pavlovic, M; Savic, S; Tamburic, S; Tasic-Kostov, M; Vuleta, G, 2010
)
3.25

Effects

Lactobionic acid (LBA) has been widely used in the food, pharmaceutical, and cosmetic industries. It has rapidly emerged as a strategic functionalization molecule in the development of nanoparticle-based platforms and biomaterials.

ExcerptReferenceRelevance
"Lactobionic acid (LBA) has recently emerged as an important substance in various industries, such as cosmetics, foods, and pharmaceuticals. "( Efficient isolation of new lactobionic acid-producing microorganisms from environmental samples by colloidal calcium carbonate agar plate-based screening.
Eom, GT; Oh, YR, 2022
)
2.46
"Lactobionic acid (LBA) has been widely used in the food, pharmaceutical, and cosmetic industries. "( Efficient production of lactobionic acid using genetically engineered Pseudomonas taetrolens as a whole-cell biocatalyst.
Eom, GT; Han, JJ; Hong, SH; Jang, YA; Oh, YR, 2020
)
2.31
"Lactobionic acid (LBA) has rapidly emerged as a strategic functionalization molecule in the development of nanoparticle-based platforms and biomaterials with promising therapeutic applications. "( Exploiting the bioengineering versatility of lactobionic acid in targeted nanosystems and biomaterials.
Alonso, S, 2018
)
2.18
"Lactobionic acid has appeared on the commercial scene as a versatile polyhydroxy acid with numerous promising applications in the food, medicine, pharmaceutical, cosmetics and chemical industries. "( Bio-production of lactobionic acid: current status, applications and future prospects.
Alonso, S; Díaz, M; Rendueles, M, 2013
)
2.17

Bioavailability

ExcerptReferenceRelevance
" Ferric lactobionate shows poorer bioavailability than ferrous ion in the presence of Cu, but milk can be an excellent vehicle for Fe or Cu supplementation."( Bioavailability of iron- and copper-supplemented milk for Mexican school children.
Green, R; Hegenauer, J; Rivera, R; Ruiz, R; Saltman, P, 1982
)
0.26
" The nanocomplex enhanced bioavailability of hydrophobic drugs, efficient tumor cell targeting and exhibited pH-responsive function and sustained release profile."( Simultaneous inhibition of growth and metastasis of hepatocellular carcinoma by co-delivery of ursolic acid and sorafenib using lactobionic acid modified and pH-sensitive chitosan-conjugated mesoporous silica nanocomplex.
Fan, L; Jiang, K; Li, T; Shao, J; Zhao, R; Zheng, G, 2017
)
0.66
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" Bulk quercetin has low bioavailability and thus, from obtained data we suggest that LA-Q-ORMOSIL nanoparticles provide high therapeutic value in protecting experimental animals against CP-induced liver injury."( Lactobionic Acid Conjugated Quercetin Loaded Organically Modified Silica Nanoparticles Mitigates Cyclophosphamide Induced Hepatocytotoxicity.
Flora, SJ; Naqvi, S; Sharma, H, 2019
)
1.96

Dosage Studied

ExcerptRelevanceReference
" In a third in vivo study, protamine sulfate when injected intravenously into the bloodstream of a group of primate was found to completely neutralize the anticoagulant effects of a previously administered dosage of Aprosulate."( Protamine sulfate neutralization of the anticoagulant activity of Aprosulate, a synthetic sulfated lactobionic acid amide.
Fareed, J; Hoppensteadt, D; Jeske, W; Kijowski, R, 1994
)
0.51
" Oral administration to rats of up to 10 mL/kg bodyweight (bw)/day (equivalent to a total organic solids dosage of 900 mg/kg bw/day or a Lactose Oxidase dosage of 344 LOXU/kg bw/day) for 13 weeks did not cause any adverse effect."( Toxicological studies on Lactose Oxidase from Microdochium nivale expressed in Fusarium venenatum.
Ahmad, SK; Brinch, DS; Friis, EP; Pedersen, PB, 2004
)
0.32
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
antioxidantA substance that opposes oxidation or inhibits reactions brought about by dioxygen or peroxides.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
disaccharideA compound in which two monosaccharides are joined by a glycosidic bond.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
GLI family zinc finger 3Homo sapiens (human)Potency26.60320.000714.592883.7951AID1259369
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (37)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (219)

TimeframeStudies, This Drug (%)All Drugs %
pre-199017 (7.76)18.7374
1990's36 (16.44)18.2507
2000's33 (15.07)29.6817
2010's95 (43.38)24.3611
2020's38 (17.35)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 39.19

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index39.19 (24.57)
Research Supply Index5.45 (2.92)
Research Growth Index5.07 (4.65)
Search Engine Demand Index114.10 (26.88)
Search Engine Supply Index3.95 (0.95)

This Compound (39.19)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (0.87%)5.53%
Reviews6 (2.62%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other221 (96.51%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]